01 June 2011
A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritisMaria de los Angeles PinedaBCDEF, Sarah Frances ThompsonBCDE, Kelly SummersBDE, Faye de LeonCE, Janet PopeADE, Gregor ReidADE
Med Sci Monit 2011; 17(6): CR347-354
Background: To examine the effect of probiotics as adjunctive therapy for the treatment of rheumatoid arthritis (RA). A sample size of 30 subjects was calculated to determine a moderate effect.
Material/Methods: A three month double-blind, placebo-controlled study was performed using probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 capsules administered orally. Inclusion criteria required at least 4 swollen and 4 tender joints and stable medications with no steroids for at least 1 month prior to and during the study. Twenty-nine patients with RA were randomized to treatment. ACR20 responses, serum cytokine levels and safety parameters were assessed.
Results: Fifteen patients were randomized to the probiotic group, and 14 to placebo. Three subjects in the probiotic (20%) and one in the placebo group (7%) achieved an ACR20 response (p= 0.33). There was no statistically significant difference between individual components of the ACR20 criteria. Changes in cytokines favored placebo over probiotic. There was a significant improvement in the Health Assessment Questionnaire (HAQ) score in the probiotic group from visit 1 to visit 3 (p=0.02) but no between-group differences.
Conclusions: Due to inclusion criteria, patients selected for the study had stable RA with chronic synovitis, and thus it may have been difficult for an adjunctive therapy to demonstrate improvement within 3 months. Although probiotics did not clinically improve RA as measured by the ACR20, it is interesting that there was functional improvement seen within the probiotic group compared to placebo.
Keywords: Placebos, Pilot Projects, Inflammation Mediators - blood, Double-Blind Method, Cytokines - blood, Arthritis, Rheumatoid - drug therapy, Antirheumatic Agents - therapeutic use, Probiotics - therapeutic use, Questionnaires
01 January 2023 : EditorialEditorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030
Med Sci Monit 2023; 29:e939357
26 January 2023 : EditorialEditorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
Med Sci Monit In Press; DOI: 10.12659/MSM.939580
19 January 2023 : Clinical ResearchEvaluation of Health-Related Quality of Life and Mental Health in 729 Medical Students in Indonesia During ...
Med Sci Monit In Press; DOI: 10.12659/MSM.938892
19 January 2023 : Clinical ResearchDetermining the Impact of the COVID-19 Pandemic on Dental Care in the Serbian Adult Population: An Online Q...
Med Sci Monit 2023; 29:e939238
31 Jan 2023 : Clinical ResearchBalloon Dilation Eustachian Tuboplasty Combined with Tympanotomy Tube Insertion for Treatment of Refractory...
Med Sci Monit In Press; DOI: 10.12659/MSM.938879
31 Jan 2023 : Clinical ResearchComparison of Vision Correction and Corneal Thickness at 180-Day Follow-Up After Femtosecond Laser-Assisted...
Med Sci Monit In Press; DOI: 10.12659/MSM.939099
30 Jan 2023 : Clinical ResearchSplenic Artery Steal Syndrome in Patients with Liver Cirrhosis: A Retrospective Clinical Study
Med Sci Monit In Press; DOI: 10.12659/MSM.938998
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292